News

Latest news from the Science Center, the companies we support and the innovation ecosystem.

April 16, 2019 | Resident & Alumni News

Integral Molecular Doubles Antibody Characterization Capacity Within Philadelphia's Science Center

Integral Molecular, the industry leader in membrane protein solutions, today announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array (MPA). Integral Molecular recently acquired office and laboratory space, which enabled the company to double its antibody characterization capabilities.

Read More
March 19, 2019 | Resident & Alumni News

Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced

Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, today announced that Mihir Shah of UE LifeSciences and Pierluigi Paracchi of Genenta Science were chosen as winners of the second Lyfebulb-Helsinn Innovation Summit and Awards in Oncology. Mihir received the Lyfebulb-Helsinn Innovation Award, and Pierluigi received The Squinto-LePera award, which was presented by Dr. Stephen Squinto and Denise LePera. The awards recognize outstanding innovations by Patient Entrepreneurs which advance solutions in the prevention, management or care of cancer, and have the potential to be commercialized.

Read More
March 12, 2019 | Resident & Alumni News

Oncoceutics licenses rights for its anti-cancer compound to Ohara

US based Oncoceutics, Inc. has announced the outlicense of the rights to the company’s lead compound, ONC201, for Japan to Ohara Pharmaceutical Co., Ltd. In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a right of first refusal for the company’s next generation compound, ONC206, in these territories.

Read More
March 1, 2019 | Resident & Alumni News

Spark Therapeutics’ $4.8B deal confirmed as biggest-ever VC-backed exit in Philly

The eye-popping $4.8 billion sticker price on Spark Therapeutics’ acquisition deal with Roche announced on Monday is shaping up to be the largest exit ever within city limits for a venture-backed company, according to data from financial data provider PitchBook and the Philadelphia Alliance for Capital and Technologies (PACT).

Read More
March 1, 2019 | Resident & Alumni News

Etsy for gaming tools? Meet the Philly startup that wants to help you ace that video game

Once upon a time, video games were pretty basic. Consider Pac-Man, the chomping mouth that devoured small dots while moving through a maze. Now, games are so complex that players need Excel spreadsheets, calculators, and troop-deployment schedules to wage virtual wars, capture castles, and build strategic alliances with players in other states and countries. Having an engineering degree helps.

Read More
February 25, 2019 | Resident & Alumni News

Roche agrees to buy Philadelphia biotech Spark Therapeutics for $4.8 billion

Spark Therapeutics Inc., founded by two researchers from Children’s Hospital of Philadelphia, has agreed to be sold to Switzerland-based Roche Holding AG in a deal valued at $4.8 billion, the University City-based gene-therapy developer announced Monday morning.

Read More
February 7, 2019 | Resident & Alumni News

bioMérieux Acquires Invisible Sentinel, a US-Based Company Specialized in Food and Beverage Molecular Testing

bioMérieux (Paris:BIM), a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc. This company, based in Philadelphia (PA) develops, manufactures and markets innovative and user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in food and beverage.

Read More
February 7, 2019 | Resident & Alumni News

$75 million deal: Invisible Sentinel sold to French biotech company

A Philadelphia life sciences company that developed DNA-based technology to quickly detect pathogens in food and beverages including wine and beer was acquired by French biotechnology company bioMérieux for $75 million.

Read More
January 23, 2019 | Resident & Alumni News

Philadelphia gene therapy company awarded $4.5M from Cystic Fibrosis Foundation

Talee Bio Inc., a Philadelphia biopharmaceutical company developing gene therapy treatments for cystic fibrosis, received a grant of up to $4.5 million from the Cystic Fibrosis Foundation.

Read More
January 23, 2019 | Resident & Alumni News

With human drugs, a Silicon Valley startup hopes to deliver precision medicine to dogs

When pet dogs are diagnosed with cancer, they typically get surgery, chemotherapy, or radiation — that is, of course, if their owner opts to treat it.

Read More
{

Sign up to receive email updates from Flying Slippers!

Kristen Fitch

Director, Marketing

kfitch [at] sciencecenter.org